56 material Form 8-K filings that 54 companies we cover made with the SEC in November 2023, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Veeco reported third-quarter 2023 revenue of $177.4 million, up from $171.9 million a year earlier, and GAAP net income of $24.6 million ($0.42 per diluted share), up from $15.0 million ($0.27). Its conference presentation raised the 2023 non-GAAP EPS outlook to $1.55 to $1.65 from $1.30 to $1.50, and the fourth-quarter revenue guidance is $155 million to $175 million.
Q3 2023 revenue $177.4 million vs $171.9 million in Q3 2022
GAAP diluted EPS $0.42 vs $0.27; non-GAAP diluted EPS $0.53 vs $0.45
Q4 2023 guidance: revenue $155 million to $175 million; non-GAAP diluted EPS $0.35 to $0.45
2023 non-GAAP EPS outlook raised to $1.55 to $1.65 from $1.30 to $1.50; nine-month GAAP net loss of $52.0 million reflects a $97 million loss on debt extinguishment
Jones Lang LaSalle signed Amendment No. 5 to its multicurrency credit agreement on November 3, 2023, setting borrowing capacity at $3.3 billion and extending maturity from April 2026 to November 2028. The amendment also changed Adjusted EBITDA adjustments, the Canadian dollar index rate, and sustainability targets, and the company said the longer maturity provides liquidity and flexibility.
Borrowing capacity under the Credit Agreement is $3.3 billion.
Maturity extended from April 2026 to November 2028.
Canadian dollar loans move from CDOR to the Canadian Overnight Repo Rate Average.
Sustainability incentives now include greenhouse gas reduction targets and certification of JLL-occupied buildings over 10,000 square feet by 2030.
Krystal Biotech reported third quarter 2023 results, with net income of $80.7 million, or $2.88 per basic share, compared with a net loss of $29.9 million a year earlier. The result was driven by a $100 million gain from the sale of a Priority Review Voucher, while the company's loss from operations was $26.0 million and its first VYJUVEK product revenue was $8.6 million. Cash, cash equivalents and investments totaled $598.6 million at September 30, 2023.
Q3 2023 net income was $80.7 million, including a $100 million gain from the sale of a Priority Review Voucher.
Q3 2023 product revenues, net were $8.6 million, with 284 VYJUVEK Patient Start Forms received as of the end of the quarter.
Nine-month 2023 net income was $2.2 million, compared with a net loss of $107.9 million for the same period in 2022.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.